Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, outlines maintenance therapies for urothelial carcinoma, specifically the key conclusions from a double-blind, randomized, phase II trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma is discussed. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
